Facebook Twitter YouTube  
Contact Us
Search Clinical Trials
Home > Clinical Trials & Research > Search Clinical Trials
Print

Clinical Trials & Research

Search Clinical Trials

Clinical Trials

New Search
Title   Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Description   The purpose of this trial is to study the side effects and best dose of vorinostat and azacitidine in treating patients with myelodysplastic syndromes or acute myeloid leukemia.

Vorinostat may stop the growth of cancer or abnormal cells by blocking some of the enzymes needed for cell growth.

Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer or abnormal cells, either by killing the cells or by stopping them from dividing.

Giving vorinostat together with azacitidine may kill more cancer or abnormal cells.
Eligibility Criteria   To be eligible for this study, patients must meet several criteria, including but not limited to the following:

* Patient must be 18 Years and older

* Patient has histologically confirmed diagnosis of 1 of the following:

-Refractory anemia (RA)
-RA with ringed sideroblasts (RARS) RA with excess blasts (RAEB)
-RAEB in transformation
-Chronic myelomonocytic leukemia
-Classified according to International Prognostic Scoring System (IPSS) criteria as intermediate-1, intermediate-2, or high-risk disease.

* Patient has ife expectancy of more than 2 months

* Patient has had no other malignancy within the past 3 years

* Patient has no HIV positivity
Principal Investigator   Amit Verma, MD
Phone   (718) 405-8505
Contact Email   averma@montefiore.org
Post Date   10/25/2006
Protocol Number   06-08-373/West
Status   Unknown
Current Trial Type   Interventional
Montefiore Clinical Trial   No
CHAM Clinical Trial   No